Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Controlled Human Malaria Infection (CHMI) Study to Evaluate the Safety, Immunogenicity, and Efficacy of a Late Liver Stage-arresting, Replication-competent Plasmodium Falciparum Sporozoite Vaccine (Sanaria® PfSPZ-LARC2 Vaccine) Administered as a Single Dose to Malaria-exposed Adults in Burkina Faso

NCT07730177 is registered in ClinicalTrials.gov with Sanaria Inc. as lead sponsor.

NCT NCT07730177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07730177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Controlled Human Malaria Infection (CHMI) Study to Evaluate the Safety, Immunogenicity, and Efficacy of a Late Liver Stage-arresting, Replication-competent Plasmodium Falciparum Sporozoite Vaccine (Sanaria® PfSPZ-LARC2 Vaccine) Administered as a Single Dose to Malaria-exposed Adults in Burkina Faso
Lead sponsor
Sanaria Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
January 31, 2028
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria (plasmodium falciparum)